Webster Bank’s CRISPR Therapeutics CRSP Stock Holding History

Webster Bank’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-140	Closed	-$9.54K	–	623
2024 Q1	$9.54K	Sell	140 -231	-62%	-$16.5K	﹤0.01%	476
2023 Q4	$23.2K	Hold	371	–	–	﹤0.01%	419
2023 Q3	$16.8K	Hold	371	–	–	﹤0.01%	418
2023 Q2	$20.8K	Sell	371 -285	-43%	-$16.2K	﹤0.01%	399
2023 Q1	$29.7K	Hold	656	–	–	﹤0.01%	384
2022 Q4	$27K	Hold	656	–	–	﹤0.01%	386
2022 Q3	$43K	Hold	656	–	–	0.01%	327
2022 Q2	$40K	Hold	656	–	–	0.01%	336
2022 Q1	$41K	Hold	656	–	–	﹤0.01%	356
2021 Q4	$50K	Buy	656 +425	+184%	+$37.1K	0.01%	345
2021 Q3	$26K	Hold	231	–	–	﹤0.01%	392
2021 Q2	$37K	Hold	231	–	–	﹤0.01%	355
2021 Q1	$28K	Hold	231	–	–	﹤0.01%	377
2020 Q4	$35K	Sell	231 -89	-28%	-$10.5K	﹤0.01%	355
2020 Q3	$27K	Buy	+320	New	+$28.4K	﹤0.01%	347
2020 Q2	–	Sell	-420	Closed	-$18K	–	514
2020 Q1	$18K	Hold	420	–	–	﹤0.01%	361
2019 Q4	$26K	Buy	+420	New	+$22.9K	﹤0.01%	372

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Webster Bank's CRSP Position: Q2 2024 in Review

Webster Bank sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 140 shares — an estimated $9.54K sold.

Webster Bank first reported a position in CRSP in Q4 2019 and held it in 17 quarters. The position peaked at $50K in Q4 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Webster Bank reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Webster Bank sold 140 CRISPR Therapeutics shares in Q2 2024, an estimated $9.54K.
Webster Bank first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 17 quarters.
Webster Bank's CRISPR Therapeutics position peaked at $50K in Q4 2021.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Webster Bank's 13F filing for Q2 2024, filed 12 Jul 2024.